Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/QAD.0000000000003495 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Summary of the National Advisory Committee on Immunization (NACI) Statement-Updated guidance on Imvamune in the context of a routine immunization program.
Can Commun Dis Rep
January 2025
Department of Medicine, University of Alberta, Edmonton, AB.
Background: Mpox is a viral illness related to smallpox. It can cause flu-like symptoms and a rash, and in severe cases, can lead to hospitalization or death. The Imvamune® vaccine offers protection against mpox.
View Article and Find Full Text PDFMpox-Induced Metabolic Alterations.
J Cell Mol Med
January 2025
Department of Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
The resurgence of mpox as a global health threat highlights the need to understand its interaction with host cell metabolism. Unlike other well-studied viruses, research on mpox is limited, particularly regarding its impact on cellular processes. In this article, we explore how mpox might manipulate metabolic pathways-such as glycolysis, lipid synthesis and mitochondrial dynamics-to enhance its replication and evade immune responses.
View Article and Find Full Text PDFMpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
School of Human Sciences, London Metropolitan University, London, UK.
Mpox, formerly known as monkeypox, is a zoonotic disease caused by the Mpox virus (MPXV), which has recently attracted global attention due to its potential for widespread outbreaks. Initially identified in 1958, MPXV primarily spreads to humans through contact with infected wild animals, particularly rodents. Historically confined to Africa, the virus has expanded beyond endemic regions, with notable outbreaks in Europe and North America in 2022, especially among men who have sex with men (MSM).
View Article and Find Full Text PDFRisk factors for human infection with mpox among the Mexican population with social security.
PLoS One
January 2025
Epidemiologic Surveillance Coordination, Mexican Institute of Social Security, Mexico City, Mexico.
Background: The 2022 mpox outbreak marked a significant shift in the epidemiology of this zoonotic disease, traditionally confined to Central and West Africa. With over 80 countries reporting cases, this outbreak was characterized by a rapid spread in non-endemic regions, leading to more than 70,000 confirmed cases globally.
Objective: To quantify the cumulative incidence of mpox and identify associated factors of mpox among the Mexican population affiliated by the Mexican Social Security Institute during the 2022-2023 outbreak.
Helminthiasis and mpox vaccination: challenges in Sub-Saharan Africa.
Infect Dis (Lond)
January 2025
Migrant and Global Health Research Organization, Mi-Hero, Italy.
The ongoing mpox outbreak in sub-Saharan Africa has highlighted the critical need for equitable vaccine access and robust logistical support. However, these factors alone are insufficient to ensure the success of vaccination campaigns in regions characterized by unique epidemiological and immunological challenges. One significant issue is the high prevalence of helminth infections, which are known to impair immune responses to vaccines, potentially reducing both short-term efficacy and long-term antibody titers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!